PT  - JOURNAL ARTICLE
AU  - Ballin, Marcel
AU  - Ioannidis, John P.A.
AU  - Bergman, Jonathan
AU  - Kivipelto, Miia
AU  - Nordström, Anna
AU  - Nordström, Peter
TI  - Time-Varying Risk of Death After SARS-CoV-2-Infection in Long-Term Care Facility Residents: A Matched Cohort Study
AID  - 10.1101/2022.03.10.22272097
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.10.22272097
4099  - http://medrxiv.org/content/early/2022/06/27/2022.03.10.22272097.short
4100  - http://medrxiv.org/content/early/2022/06/27/2022.03.10.22272097.full
AB  - Background SARS-CoV-2 confers high risk of short-term death in residents of long-term care (LTC) facilities, but longer-term risk among survivors is unclear.Methods We extended the follow-up period of a previous, propensity score-matched retrospective cohort study based on the Swedish Senior Alert register. N=3731 LTC residents with documented SARS-CoV-2 until 15 September 2020 were matched to 3731 uninfected controls using time-dependent propensity scores on age, sex, health status, comorbidities, and prescription medications. In a sensitivity analysis, matching included also geographical region and Senior Alert registration time. The outcome was all-cause mortality over 8 months (until October 24, 2020). The absolute risk of death was examined using Kaplan-Meier plots. Hazard ratios (HR) for death over time were estimated using flexible parametric models with restricted cubic splines. Cox regression was used to estimate HRs and 95% confidence intervals (CIs) in 30-day intervals of follow-up until 210 days.Results The median age was 87 years and 65% were women. Excess mortality was highest 5 days after documented infection (HR 19.1, 95% CI, 14.6-24.8), after which excess mortality decreased. From the second month onwards, mortality rate became lower in infected residents than controls. The HR for death during days 61-210 of follow-up was 0.41 in the main analysis (95% CI, 0.34-0.50) and 0.76 (95% CI, 0.62-0.93) in the sensitivity analysis. Median survival of uninfected controls was 1.6 years, which was much lower than the national life expectancy in Sweden at age 87 (5.05 years in men, 6.07 years in women).Conclusions No excess mortality was observed in LTC residents who survived the acute SARS-CoV-2 infection. Life expectancy of uninfected residents was much lower than that of the general population of the same age and sex. This suggests that LTC resident status should be accounted for in years-of-life-lost estimates for COVID-19 burden of disease calculations.Impact statement We certify that this work is novel. This research adds to the literature by showing there was no excess mortality observed in long-term care facility residents who survived the acute SARS-CoV-2 infection, and that life expectancy of uninfected residents was much lower than that of the general population of same age and sex. This has major repercussions for estimation of years of life lost in infected long term care facility residents.Key pointsSARS-CoV-2 infection sharply increased mortality risk among residents of long-term care (LTC) facilities in the first month.After the first month, the mortality risk in infected residents rapidly returned to baseline and dropped below the mortality risk of uninfected controls, where it remained lower for 8 months of follow-up.Median survival of uninfected controls was 1.6 years, which was much lower than national life expectancy in Sweden at age 87.Why does this matter?Whereas LTC residents who recover from SARS-CoV-2 infection may be concerned about having residual debilitation caused by the infection, we found no excess mortality was in those who survived the acute infection.Because life expectancy of uninfected residents was much lower than that of the general population of same age and sex, LTC resident status should be accounted for in estimations of years of life lost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received funding used for salaries from Foundation Stockholms Sjukhem (MK), Academy of Finland (MK), Laekarsaellskapet (MK), and the Swedish Research Council (MK, AN, PN). The funders had no role in any part of this manuscript or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swedish Ethical Review Authority (no. 2020-02552), which waived the informed consent requirement given the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data files used for the present study is publicly unavailable according to regulations under Swedish law, but can be applied for at each of the respective registry holders.